Siepe Matthias, Heilmann Claudia, von Samson Patrick, Menasché Philippe, Beyersdorf Friedhelm
Department of Cardiovascular Surgery, University Clinic, Albert-Ludwigs-University Freiburg, Hugstetterstrasse 55, 79106 Freiburg, Germany.
Eur J Cardiothorac Surg. 2005 Aug;28(2):318-24. doi: 10.1016/j.ejcts.2005.03.044.
Several human organs are not capable of functional regeneration following a tissue defect and react with scar formation. In stem cell transplantation, undifferentiated or partly differentiated precursor cells are applied to defective tissue for therapeutic regeneration. After promising preclinical investigations, the transplantation of autologous stem cells for myocardial infarction treatment is being transferred to clinical use. Mesenchymal stem cells and endothelial precursor cells derived from the bone marrow or circulating blood as well as skeletal myoblasts are employed in clinical trials. Furthermore, indications for cell transplantation and delivery routes vary considerably throughout current investigations. Initial results suggest a potential for restoration of cardiac function in stem cell-treated patients; however, the mechanisms are not fully understood. This overview will focus on objectives, recent achievements, and future perspectives of diverse stem cell transplantation approaches.
人体的几个器官在组织缺损后无法进行功能性再生，而是会形成瘢痕。在干细胞移植中，未分化或部分分化的前体细胞被应用于有缺陷的组织以实现治疗性再生。经过有前景的临床前研究后，用于治疗心肌梗死的自体干细胞移植正在转向临床应用。源自骨髓或循环血液的间充质干细胞和内皮前体细胞以及骨骼肌成肌细胞正在临床试验中得到应用。此外，在当前的研究中，细胞移植的适应症和递送途径差异很大。初步结果表明干细胞治疗的患者有恢复心脏功能的潜力；然而，其机制尚未完全了解。本综述将聚焦于各种干细胞移植方法的目标、近期成果和未来前景。
